NCT03765177 - CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 16, 2019

Primary Completion Date

January 31, 2027

Study Completion Date

June 30, 2042

Conditions

Acute Lymphoblastic LeukemiaNon-Hodgkin's LymphomaChronic Lymphocytic Leukemia

Interventions

BIOLOGICAL

CLIC-1901

Participants will undergo (a) lymphodepletion with cyclophosphamide and fludarabine, followed by (b) infusion of autologous CLIC-1901 CAR-T cells. All treatments will be delivered intravenously.

Trial Locations (3)

V5Z1M9

RECRUITING

Vancouver General Hospital, Vancouver

R3E 0V9

NOT_YET_RECRUITING

CancerCare Manitoba, Winnipeg

K1H 8L6

RECRUITING

The Ottawa Hospital - General Campus, Ottawa